MX2009004437A - Use of a mt kinase inhibitor for treating or preventing brain cancer. - Google Patents

Use of a mt kinase inhibitor for treating or preventing brain cancer.

Info

Publication number
MX2009004437A
MX2009004437A MX2009004437A MX2009004437A MX2009004437A MX 2009004437 A MX2009004437 A MX 2009004437A MX 2009004437 A MX2009004437 A MX 2009004437A MX 2009004437 A MX2009004437 A MX 2009004437A MX 2009004437 A MX2009004437 A MX 2009004437A
Authority
MX
Mexico
Prior art keywords
brain cancer
treating
preventing
kinase inhibitor
brain
Prior art date
Application number
MX2009004437A
Other languages
Spanish (es)
Inventor
Eddy Jean Edgard Freyne
Timothy Pietro Suren Perera
Michel Marie Francois Janicot
Martin John Page
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009004437A publication Critical patent/MX2009004437A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is concerned with the finding that some the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacy clo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of a primary brain cancer or brain metastasis. It accordingly provides methods for treating, preventing, delaying or mitigating brain cancer, or for preventing or slowing proliferation of cells of brain origin.
MX2009004437A 2006-10-27 2007-10-25 Use of a mt kinase inhibitor for treating or preventing brain cancer. MX2009004437A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86316206P 2006-10-27 2006-10-27
EP06123058 2006-10-27
US97616807P 2007-09-28 2007-09-28
PCT/EP2007/061498 WO2008049901A1 (en) 2006-10-27 2007-10-25 Use of a mt kinase inhibitor for treating or preventing brain cancer

Publications (1)

Publication Number Publication Date
MX2009004437A true MX2009004437A (en) 2009-05-11

Family

ID=38925659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004437A MX2009004437A (en) 2006-10-27 2007-10-25 Use of a mt kinase inhibitor for treating or preventing brain cancer.

Country Status (10)

Country Link
EP (1) EP2077843A1 (en)
JP (1) JP2010507625A (en)
KR (1) KR20090091119A (en)
AU (1) AU2007310842A1 (en)
CA (1) CA2664145A1 (en)
EA (1) EA200970418A1 (en)
IL (1) IL198347A0 (en)
MX (1) MX2009004437A (en)
NO (1) NO20092046L (en)
WO (1) WO2008049901A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives

Also Published As

Publication number Publication date
NO20092046L (en) 2009-07-01
IL198347A0 (en) 2010-02-17
EA200970418A1 (en) 2009-10-30
AU2007310842A1 (en) 2008-05-02
JP2010507625A (en) 2010-03-11
WO2008049901A1 (en) 2008-05-02
KR20090091119A (en) 2009-08-26
CA2664145A1 (en) 2008-05-02
EP2077843A1 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
WO2007087245A3 (en) Ret tyrosine kinase inhibition
TN2011000298A1 (en) Compounds useful for inhibiting chk1
WO2006113703A3 (en) Carboline derivatives useful in the treatment of cancer
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
HK1130438A1 (en) Using pi3k and mek modulators in treatments of cancer
MX2011012037A (en) Heteroaryl compounds as pikk inhibitors.
TW200801008A (en) Protein kinase inhibitors
MX346379B (en) Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer.
EA200801118A1 (en) FLT3 KINASE INHIBITION METHOD
MX2008012852A (en) Quinazolines for pdk1 inhibition.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2013011329A (en) Combinations of akt inhibitor compounds and erlotinib, and methods of use.
MX2009006627A (en) Quinazolines for pdk1 inhibition.
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
GEP20125368B (en) Kinase inhibitors
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
UA98141C2 (en) Methods of treating with quinaxoline inhibitors of pi3k-alpha
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MX2008015775A (en) Compounds and compositions for treatment of cancer.
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
JO3145B1 (en) Compounds useful for inhibiting chk1
EA200870454A1 (en) METHOD OF INHIBITING C-KIT KINASE
WO2008121467A3 (en) Combination therapy for treating cancer